Capstone Investment Advisors
PACB icon

Capstone Investment Advisors’s Pacific Biosciences PACB Stock Holding History

Capstone Investment Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-53,800
Closed -$278K – 1431
2019
Q3 		$278K Buy
+53,800
New +$301K ﹤0.01% 1187

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capstone Investment Advisors's PACB Position: Q2 2024 in Review

Capstone Investment Advisors sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 61,790 shares — an estimated $232K sold.

Capstone Investment Advisors first reported a position in PACB in Q2 2016 and held it in 9 quarters. The position peaked at $4.57M in Q4 2018. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Capstone Investment Advisors reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 61,790 Pacific Biosciences shares in Q2 2024, an estimated $232K.
  • Capstone Investment Advisors first reported a position in Pacific Biosciences in Q2 2016 and held it in 9 quarters.
  • Capstone Investment Advisors's Pacific Biosciences position peaked at $4.57M in Q4 2018.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Capstone Investment Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.